Genetically engineered (chimeric) antibodies.
The diversity, specificity, and biologic activity of antibodies make them potentially ideal reagents in the clinic and the laboratory, but conventional antibodies do not always fill the bill. Naturally occurring antibodies are heterogeneous, and human hybridoma antibodies are hard to produce. Genetic engineering techniques offer antibodies with just the properties desired.
Morrison
S L
SL
Molecular Biology Institute, University of California, Los Angeles.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics; D000920:Antibody-Dependent Cell Cytotoxicity; D002678:Chimera; D004262:DNA Restriction Enzymes / Q000378:metabolism; D015321:Gene Rearrangement; D005818:Genetic Engineering; D006801:Humans; D006825:Hybridomas / Q000276:immunology*; D007127:Immunoglobulin Constant Regions / Q000235:genetics; D007132:Immunoglobulin Isotypes / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D009154:Mutation; D014162:Transfection
D000911:Antibodies, Monoclonal; D007127:Immunoglobulin Constant Regions; D007132:Immunoglobulin Isotypes; D007135:Immunoglobulin Variable Region; D004262:DNA Restriction Enzymes